Clinical utility of a tumor-naïve circulating tumor DNA (ctDNA) test to predict outcomes in patients with advanced testicular germ cell tumors. Treatment of poor-risk non seminomatous germ-cell tumors ...

Background: Microsatellite instability- high (MSI-H) tumors have high rates of response to immune checkpoint blockade (ICB) with prolonged durability of response. However, predicting who will have a ...

Tumor M2 Pyruvate Kinase: A Tumor Marker and its Clinical Application in Gastrointestinal Malignancy. Philip D. Hardt, MD, PhD; Nils Ewald, MD. Disclosures. Expert Rev Mol Diagn. 2008;8(5):579-585.

Organ-specific Markers in Circulating Tumor Cell Screening An Early Indicator of Metastasis-Capable Malignancy. Patrizia Paterlini-Bréchot. Disclosures. Future Oncol. 2011;7(7):849-871. ...

yolk sac tumours (post pubertal type) So, for example, you might have a mix of some teratoma cells and some embryonal carcinoma cells. It's also possible to have pure teratomas. These non seminoma ...

Autophagy is the body’s way of cleaning out damaged cells, in order to regenerate newer, healthier cells. It allows your body to remove the dysfunctional cells.

Tumour marker blood tests . Tumour markers are substances that might be raised if there is a cancer. They’re usually proteins. They can be found in the blood, urine or body tissues. You might also ...

VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma Dongshen Ma 1† Yubo Wang 1† Qingqing Shen 1,2 Xinyu Liu 1,2 Wenxin Lu 2 Shaoqi Li 1 Qianqian ...

Notably, tumor marker pseudoprogression has also been observed in gastric cancer, in addition to lung cancer and HCC, suggesting it could be a broader phenomenon across cancer types (15, 37–39).